Steven Cohen Cerevel Therapeutics Holdings, Inc. Transaction History

Point72 Asset Management, L.P.

$36 Billion
Q2 2024

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 35,000 shares of CERE stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares

35,000

Previous 35,000 -0.0%

Holding current value

Previous $1.43 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$22.82 - $35.32 $6.66 Million - $10.3 Million	-291,729 Reduced 72.37%	111,400 $2.72 Million
Q4 2022 Feb 14, 2023	SELL	$25.35 - $31.96 $17.3 Million - $21.8 Million	-681,111 Reduced 62.82%	403,129 $12.7 Million
Q3 2022 Nov 14, 2022	BUY	$25.5 - $41.42 $22.5 Million - $36.5 Million	881,940 Added 435.96%	1,084,240 $30.6 Million
Q2 2022 Aug 15, 2022	BUY	$20.62 - $37.15 $4.17 Million - $7.52 Million	202,300 New	202,300 $5.35 Million
Q4 2021 Feb 14, 2022	SELL	$29.21 - $44.64 $4.13 Million - $6.31 Million	-141,400 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$21.26 - $38.85 $4.83 Million - $8.82 Million	-227,150 Reduced 61.63%	141,400 $4.17 Million
Q2 2021 Aug 16, 2021	BUY	$12.56 - $29.69 $902,436 - $2.13 Million	71,850 Added 24.22%	368,550 $9.44 Million
Q1 2021 May 17, 2021	BUY	$12.37 - $17.74 $2.19 Million - $3.13 Million	176,700 Added 147.25%	296,700 $4.07 Million
Q4 2020 Feb 16, 2021	BUY	$9.82 - $18.27 $1.18 Million - $2.19 Million	120,000 New	120,000 $1.99 Million

Others Institutions Holding CERE

# of Institutions

242

Shares Held

154M

Call Options Held

2.19M

Put Options Held

3.87M

View Full List

About Cerevel Therapeutics Holdings, Inc.

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

More about CERE

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account